Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004) - Wikidata - awgldk - TriplyDB

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)

http://www.wikidata.org/entity/Q35012567

about

The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.The importance of the vaginal delivery route for antiretrovirals in HIV prevention.A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Acceptability in microbicide and PrEP trials: current status and a reconceptualization.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Nanocarrier for poorly water-soluble anticancer drugs--barriers of translation and solutions.Nanomedical engineering: shaping future nanomedicines.Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms Non-specific microbicide product development: then and now Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety Variations in microbicide gel acceptability among young women in the USA and Puerto Rico."Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.Degradable polyethylenimine derivate coupled to a bifunctional peptide R13 as a new gene-delivery vector The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.A molecular tweezer antagonizes seminal amyloids and HIV infection.Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women.Polymeric drugs: Advances in the development of pharmacologically active polymers.Polyethylene glycol-functionalized poly (Lactic Acid-co-Glycolic Acid) and graphene oxide nanoparticles induce pro-inflammatory and apoptotic responses in Candida albicans-infected vaginal epithelial cells Exploiting herpes simplex virus entry for novel therapeutics.Microbicides: still a long road to success Young women's experience with using videoconferencing for the assessment of sexual behavior and microbicide use.Non-Antiretroviral Microbicides for HIV Prevention.The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto Rico.Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties Methodological lessons from clinical trials and the future of microbicide research.Targeting monocytes/macrophages in the treatment of rheumatoid arthritis.Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases.Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Polypeptide-Based Conjugates as Therapeutics: Opportunities and Challenges.A recent trend of drug-nanoparticles in suspension for the application in drug delivery.The role of nanotechnology in the treatment of viral infections.The SPL7013 dendrimer destabilizes the HIV-1 gp120-CD4 complex.Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity.Targeted nanoparticles for colorectal cancer.

P2860

Q28087336-23DF06EB-0F9E-4B3F-8918-28B4ED892A6B Q28478776-4B847172-9D48-4B0D-BADB-AD6FADBC486B Q30412592-43D6B4F0-F0EF-4C61-AC29-9711B0AA3469 Q30414890-563D75CC-2735-4A3C-9B57-3A3D8D08A170 Q30431343-9AF8E0BF-CA05-4D36-BE73-6C2167BA2D47 Q33631838-935A6BE3-D18C-47A0-BDC8-BC6626F39E3B Q33821090-94526FF8-04CE-4202-87C5-DE0AD951424C Q33962553-4CF7C7D9-09EC-4157-BDE0-601A85E7BCC7 Q35019550-51250BAD-13E0-4FA6-8612-1CE1DDF7D099 Q35213456-00561CE7-06F3-4537-9B96-F2FD4565499D Q35274791-A594B385-F1D8-4810-8026-0D60FCF31314 Q35345283-35B87879-C800-4317-AD7C-4D05353B857B Q35681023-E9DF0AA0-C076-4E0A-8EC6-61DEBF33BBBA Q35691650-24B336DE-77FD-4AB4-B490-0A040D3A4AC7 Q35736962-8AB7B7AB-3222-42FC-B8E6-A467094C8BA2 Q35821070-A9B029DC-09DB-46A9-9A79-9DAE1DD6C821 Q35822713-FEB6D051-BBA1-4493-87C8-2EB355F3F228 Q35954283-B026BEAD-4D0C-442A-9554-62A1D07BC0A8 Q36068677-9DEA930C-FE75-4895-B9ED-CBEA34DB24BE Q36307604-39D6E6A1-8AD8-43A4-B24D-76A2590D78EF Q36332073-78F5DFE7-B8B5-40B0-B030-288497736E04 Q37030702-67592268-A553-4422-A92D-46C34C694BC3 Q37130757-24641FAB-7BF8-43E2-814B-036441563259 Q37261596-7E8FC2C6-7C94-407F-AEEA-14F08D56D463 Q37317845-BF923BB4-A2CC-4A84-A869-1EB672EF109E Q37373898-489579D2-8271-4F99-BB58-98CEC4539795 Q37458024-3EDC37F6-A326-4D49-BA91-5F9346AB9758 Q37597118-5D066BD0-9223-4825-B4BB-42B9013B70DD Q38062882-5F62A867-B681-4E9E-ACB4-FD89BE214440 Q38064420-D72D2B09-2E63-4C1D-B115-05BCB115A150 Q38075857-7F86EDAD-69EA-40A1-9CD0-7B482D3087DE Q38233071-2EB55B03-B84C-4FA4-AB7C-630B750D8C09 Q38248209-CB4EC3F4-0A5C-4825-A44D-FD7BB3CE5789 Q38260862-A7154A88-3543-443F-9507-D2F2C204BF22 Q38983708-199F1DFE-B1D6-491A-8708-B5594FFA2BC0 Q38985268-8CEEC797-E075-4084-80FB-9444F258E2E5 Q40106774-468E8462-ECD5-4408-AE74-713D28E5FB56 Q41192034-18FB32F9-BF8B-4C93-B699-8B6BEB5CA5BC Q42050799-E969F571-59AC-477E-8D16-B36CCAC27EA6 Q42365964-835DC37C-DC8B-4311-ABF3-9B8F7A10ABB3

P2860

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)

http://www.wikidata.org/entity/Q35012567

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase 1 randomized trial of th ...... y active young women (MTN-004)

@ast

Phase 1 randomized trial of th ...... y active young women (MTN-004)

@en

type

label

Phase 1 randomized trial of th ...... y active young women (MTN-004)

@ast

Phase 1 randomized trial of th ...... y active young women (MTN-004)

@en

prefLabel

Phase 1 randomized trial of th ...... y active young women (MTN-004)

@ast

Phase 1 randomized trial of th ...... y active young women (MTN-004)

@en

P1433

Q35012567-F67AA9A9-5262-4709-90B4-EAE3869DF110

P1476

Q35012567-F4EF26E3-23AC-400B-ABB4-62AA25EF6270

P2093

Q35012567-15F52A17-A874-4620-94C4-602B88EB9520

Q35012567-380C9D39-B8AF-4FD6-9CE1-311DEE49656E

Q35012567-3D5B3A9B-AC05-4727-A6B6-0DCFE37E6726

Q35012567-428F9A62-D9CE-468A-BBB5-680FF36AB490

Q35012567-530B8BFF-71C2-4133-AF1E-643CE3ABC280

Q35012567-722A2CD5-39AE-4AB5-A5F2-B9B50E82F52F

Q35012567-7F8095CC-757B-41FE-BE4B-7C5C206C95F2

Q35012567-8CDE9E2A-E5E1-4D0C-86C4-D7D744D8C7E2

Q35012567-A13DD028-25EF-48DE-9FFD-21C2053827B2

Q35012567-AA28773C-97B4-450B-8568-12B6A3D2602F

P2860

Q35012567-03E57C58-2AA2-444C-87C7-F7E5D30A4414

Q35012567-25B48E7E-682E-4F07-A9F5-B4EDFBAF7F66

Q35012567-42F2C11C-ECA6-48BB-9C66-799EB74E6FCC

Q35012567-58CF5FB2-6AFD-4639-8D2D-423496AC1BD0

Q35012567-67140D22-B466-43E9-82C9-E339BD96DE03

Q35012567-68769E40-CE34-442A-8D61-0469F6556022

Q35012567-860812B6-4CC9-45A1-A5D8-0ADDA2D667BC

Q35012567-A664E87B-AAC0-4586-99A6-12738DF474D2

Q35012567-AFDB2222-C529-4269-917E-F67127640390

Q35012567-D25EAF70-C270-4A3F-AE81-A2B5D25275D1

P304

Q35012567-F08146CC-4B34-4389-9366-591C54781211

P31

Q35012567-2C155382-8974-4024-8DAA-C8456F707073

P356

Q35012567-2D4AE452-7DC7-4475-AAAD-BC19AD178A54

P407

Q35012567-5E5EE9D4-D4E5-426F-A650-5DBB99111986

P433

Q35012567-D3FD5CE6-3716-4741-8585-AA7472925B4E

P478

Q35012567-2AC9CC80-93F0-4593-96C8-CE5BD240DE0B

P577

Q35012567-96324227-02FD-4E42-AEC3-464E9F9D5F48

P698

Q35012567-A6FDB22A-4FBD-454A-802A-69B59A85B633

P921

Q35012567-1489606B-1D7A-4FDF-B25A-060381774E47

P932

Q35012567-1A79F4A7-7624-4F09-8057-145F40B44877

P356

QAD.0B013E328346BD3E

P1433

P1476

Phase 1 randomized trial of th ...... y active young women (MTN-004)

@en

P2093

Barbra A Richardson

http://www.w3.org/2001/XMLSchema#string

Beatrice A Chen

http://www.w3.org/2001/XMLSchema#string

Cindy Jacobson

http://www.w3.org/2001/XMLSchema#string

Clare Price

http://www.w3.org/2001/XMLSchema#string

Edward Livant

http://www.w3.org/2001/XMLSchema#string

Ian McGowan

http://www.w3.org/2001/XMLSchema#string

Irma Febo

http://www.w3.org/2001/XMLSchema#string

Kailazarid Gomez

http://www.w3.org/2001/XMLSchema#string

Karen Bruder

http://www.w3.org/2001/XMLSchema#string

MTN-004 Protocol Team

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days

Structure activity relationship of dendrimer microbicides with dual action antiviral activity

Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention.

Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection

Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.

Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes

Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model

A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.

The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies.

P304

1057-1064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E328346BD3E

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21505316

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3103767

http://www.w3.org/2001/XMLSchema#string